title: Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.
authors.affiliation: Discovery Chemistry, Small Molecule Research, pRED, Pharma Research and Early Development, Hoffmann-La Roche Inc. , 340 Kingsland Street, Nutley, New Jersey 07110, United States. yan.lou.yl1@roche.com
authors.forename: Yan
authors.initials: Y
authors.lastname: Lou
authors.forename: Timothy D
authors.initials: TD
authors.lastname: Owens
authors.forename: Andreas
authors.initials: A
authors.lastname: Kuglstatter
authors.forename: Rama K
authors.initials: RK
authors.lastname: Kondru
authors.forename: David M
authors.initials: DM
authors.lastname: Goldstein
mesh_terms: D000077329:Agammaglobulinaemia Tyrosine Kinase; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology; D020134:Catalytic Domain; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000201:enzymology; D015448:Leukemia, B-Cell / Q000188:drug therapy* / Q000201:enzymology; D008958:Models, Molecular; D011487:Protein Conformation; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000737:chemistry; D013329:Structure-Activity Relationship
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase